Zobrazeno 1 - 10
of 94
pro vyhledávání: '"heparin/ adverse effects"'
Publikováno v:
Brazilian Journal of Cardiovascular Surgery, Vol 35, Iss 6, Pp 950-957 (2020)
Abstract Introduction: Heparin-induced thrombocytopenia (HIT) is a potentially lethal complication of unfractionated or low-molecular weight heparin therapy. We aimed to determine the incidence and mortality rate of patients with positive heparin/pla
Externí odkaz:
https://doaj.org/article/f858ceb31ebc4524b8d081808152d1a2
Autor:
Richard R. Riker, Teresa L. May, Gilles L. Fraser, David J. Gagnon, Mahesh Bandara, Wesley R. Zemrak, David B. Seder
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 5, Pp 936-941 (2020)
Abstract Early reports of coronavirus disease 2019 (COVID‐19) clinical features describe a hypercoagulable state, and recent guidelines recommend prophylactic anticoagulation for patients with COVID‐19 with low‐molecular‐weight heparin, but t
Externí odkaz:
https://doaj.org/article/87d9a15e0b8140adbd0eebaebde9d3e8
Autor:
Matteo Marchetti, Stefano Barelli, Tobias Gleich, Francisco J. Gomez, Matthew Goodyer, Francesco Grandoni, Lorenzo Alberio
Publikováno v:
British journal of haematology, vol. 197, no. 6, pp. 766-790
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d52594eb0b540f1bbcfa3d4958bf109
https://doi.org/10.1111/bjh.18120
https://doi.org/10.1111/bjh.18120
Autor:
Ruben J Eck, Tessa Elling, Alex J Sutton, Jørn Wetterslev, Christian Gluud, Iwan C C van der Horst, Reinold O B Gans, Karina Meijer, Frederik Keus
Publikováno v:
BMJ (Clinical research ed.), 378. BMJ PUBLISHING GROUP
ObjectiveTo assess the benefits and harms of different types and doses of anticoagulant drugs for the prevention of venous thromboembolism in patients who are acutely ill and admitted to hospital.DesignSystematic review and network meta-analysis.Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1721369fe7bd4aa3e1ca832b1433905
https://pubmed.ncbi.nlm.nih.gov/35788047
https://pubmed.ncbi.nlm.nih.gov/35788047
Autor:
Olivier van Minnen, Annemieke Oude Lansink-Hartgring, Bas van den Boogaard, Judith van den Brule, Pierre Bulpa, Jeroen J. H. Bunge, Thijs S. R. Delnoij, Carlos V. Elzo Kraemer, Marijn Kuijpers, Bernard Lambermont, Jacinta J. Maas, Jesse de Metz, Isabelle Michaux, Ineke van de Pol, Marcel van de Poll, S. Jorinde Raasveld, Matthias Raes, Dinis dos Reis Miranda, Erik Scholten, Olivier Simonet, Fabio S. Taccone, Frederic Vallot, Alexander P. J. Vlaar, Walter M. van den Bergh
Publikováno v:
TRIALS, 23:405. BMC
Trials, 23, 1
Trials, Vol. 23, no. 1, p. 405 (2022)
Trials, 23(1):405. BioMed Central
Trials, 23(1):405. BioMed Central Ltd
Trials, 23(1):405. BioMed Central Ltd.
Trials, 23
Trials, 23, 1
Trials, Vol. 23, no. 1, p. 405 (2022)
Trials, 23(1):405. BioMed Central
Trials, 23(1):405. BioMed Central Ltd
Trials, 23(1):405. BioMed Central Ltd.
Trials, 23
Background Although life-saving in selected patients, ECMO treatment still has high mortality which for a large part is due to treatment-related complications. A feared complication is ischemic stroke for which heparin is routinely administered for w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f043c87cb1e2d735ab55dde8fae8439f
https://doi.org/10.1186/s13063-022-06367-w
https://doi.org/10.1186/s13063-022-06367-w
Autor:
Steen, W. van der, Graaf, R.A.V. de, Chalos, V., Lingsma, H.F., Doormaal, P.J. van, Coutinho, J.M., Emmer, B.J., Ridder, I. de, Zwam, W. van, Worp, H.B. van der, Schaaf, I. van der, Gons, R.A.R., Yo, L.S.F., Boiten, J., Wijngaard, I. van den, Hofmeijer, J., Martens, J., Schonewille, W., Vos, J.A., Tuladhar, A.M., Laat, K.F. de, Hasselt, B. van, Remmers, M., Vos, D., Rozeman, A., Elgersma, O., Uyttenboogaart, M., Bokkers, R.P.H., Tuijl, J. van, Boukrab, I., Berg, R. van den, Beenen, L.F.M., Roosendaal, S.D., Postma, A.A., Krietemeijer, M., Lycklama, G., Meijer, F.J.A., Hammer, S., Hoorn, A. van der, Yoo, A.J., Gerrits, D., Truijman, M.T.B., Zinkstok, S., Koudstaal, P.J., Manschot, S., Kerkhoff, H., Nieboer, D., Berkhemer, O., Wolff, L., Sluijs, P.M. van der, Voorst, H. van, Tolhuisen, M., Roos, Y.B.W.E.M., Majoie, C.B.L.M., Staals, J., Oostenbrugge, R.J. van, Jenniskens, S.F.M., Dijk, L.C. van, Hertog, H.M. den, Es, A.C.G.M. van, Lugt, A. van der, Dippel, D.W.J., Roozenbeek, B., MR CLEAN-MED Investigators
Publikováno v:
MR CLEAN-MED Investigators 2022, ' Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED) : an open-label, multicentre, randomised controlled trial ', The Lancet, vol. 399, no. 10329, pp. 1059-1069 . https://doi.org/10.1016/S0140-6736(22)00014-9
The Lancet, 399(10329), 1059-1069. ELSEVIER SCIENCE INC
The Lancet (London), 399, 1059-1069
The Lancet, 399(10329), 1059-1069. Elsevier Limited
The Lancet, 399(10329), 1059-1069. Elsevier Ltd.
The Lancet (London), 399, 10329, pp. 1059-1069
Lancet, 399(10329), 1059-1069. Elsevier Science
The Lancet, 399(10329), 1059-1069. ELSEVIER SCIENCE INC
The Lancet (London), 399, 1059-1069
The Lancet, 399(10329), 1059-1069. Elsevier Limited
The Lancet, 399(10329), 1059-1069. Elsevier Ltd.
The Lancet (London), 399, 10329, pp. 1059-1069
Lancet, 399(10329), 1059-1069. Elsevier Science
BACKGROUND: Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes. However, the effects and risks of anti-thrombotics for this indication are unknown. We therefore aimed to assess t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8953cfdde4fc4e0b25a24d129984fa64
https://research.vumc.nl/en/publications/155f1e87-ba12-4257-8269-1662795d2460
https://research.vumc.nl/en/publications/155f1e87-ba12-4257-8269-1662795d2460
Autor:
Gilles L. Fraser, David R. Gagnon, David B. Seder, Richard R. Riker, Mahesh Bandara, Teresa May, Wesley R. Zemrak
Publikováno v:
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 5, Pp 936-941 (2020)
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 5, Pp 936-941 (2020)
Early reports of coronavirus disease 2019 (COVID‐19) clinical features describe a hypercoagulable state, and recent guidelines recommend prophylactic anticoagulation for patients with COVID‐19 with low‐molecular‐weight heparin, but this would
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb540bdf1e0078aa0ca772ae745c9378
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
George Bozas, Lawrence Mbuagbaw, Robert D. McBane, Ramón Lecumberri, Kostandinos Sideras, Ziad Solh, Elie A. Akl, Mark Crowther, Giancarlo Agnelli, Michael B. Streiff, Walter Ageno, Melissa C. Brouwers, Marcello Di Nisio, Clara P.W. Klerk, Tejan Baldeh, Harry R Büller, Holger J. Schünemann, Anthony Maraveyas, Lara A Kahale, Charles L. Loprinzi, James Perry, Alfonso Iorio, Ozlem Gurunlu Alma, Ivan D. Florez, Matthew Ventresca, Gareth Griffiths, Simon Noble, Nick van Es, Ignacio Neumann, Maura Marcucci, Matthias Briel, Bernard Lebeau, Fergus Macbeth, Gordon H. Guyatt, Patrick M. Bossuyt, Gary H. Lyman, David A. Garcia, Uwe Pelzer, Qi Zhou
Publikováno v:
Lancet. Haematology, 7(10), e746-e755. Lancet Publishing Group
Background Study-level meta-analyses provide high-certainty evidence that heparin reduces the risk of symptomatic venous thromboembolism for patients with cancer; however, whether the benefits and harms associated with heparin differ by cancer type i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0149f917e93e7e70846f146bc8cea58a
https://eprints.soton.ac.uk/445064/
https://eprints.soton.ac.uk/445064/